News & Updates
Filter by Specialty:
Bisphosphonate, denosumab not linked to acute cardiovascular risk
Use of oral bisphosphonate or denosumab does not appear to increase the risk of cardiovascular events (CVEs), namely acute myocardial infarction, unstable angina, cerebrovascular accident, and transient ischemic attack, in persons with incident fracture, a study has shown.
Bisphosphonate, denosumab not linked to acute cardiovascular risk
06 May 2023Second primary melanoma tied to better survival than single primary lesion
Patients who present with second primary melanomas have better survival and thinner lesions than those presenting with single primary melanomas, reveals a study.
Second primary melanoma tied to better survival than single primary lesion
06 May 2023Hysteroscopic resection outdoes ultrasound-guided D&E for caesarean scar ectopic pregnancy
Treatment success of caesarean scar ectopic pregnancy appears to be higher with hysteroscopic resection than with ultrasound-guided dilation and evacuation (D&E), according to a study.
Hysteroscopic resection outdoes ultrasound-guided D&E for caesarean scar ectopic pregnancy
06 May 2023COVID-19 long-term sequelae and complications
Long COVID, sometimes referred to as post-acute sequelae of COVID-19, is still highly prevalent despite improved acute treatments, the emergence of newer variants, and wider vaccination coverage, says an expert at ECCMID 2023.
COVID-19 long-term sequelae and complications
06 May 2023Perampanel for idiopathic generalized epilepsy passes muster in real world
Perampanel appears to be effective and have good tolerability in patients with idiopathic generalized epilepsy treated in everyday clinical practice settings, as shown in a study.
Perampanel for idiopathic generalized epilepsy passes muster in real world
05 May 2023Immune-related AEs predict survival in cancer patients on ICI
Developing cutaneous immune-related adverse events (cirAEs) among advanced cancer patients on immune checkpoint inhibitor (ICI) appears to be a sign of longer overall survival, particularly in those with melanoma, suggests a recent study.